CellCept 500 mg film-coated tablets clinical trials
5 indexed studies · 0 currently recruiting
- Ongoing, recruitingPhase III and phase IV (Integrated)
Prospective Randomized trial of Everolimus replacing MMF/MP Acid by the RECOVAC consortium to increase VACcine response in kidney transplant patients
This study looks at how well kidney transplant patients respond to COVID-19 and shingles vaccines when their anti-rejection medication is changed. It compares two different drug treatment plans to see which one helps the body make more protective antibodies.
For: kidney transplantation · COVID-19 · Herpes ZosterNetherlands - Ongoing, recruitingTherapeutic exploratory (Phase II)
BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
This study is testing a new medicine, Tegoprubart, to see if it can help prevent the body from rejecting a new kidney after a transplant. Researchers will compare it to standard treatments to check how safe and effective it is.
For: Prophylaxis of Renal Allograft RejectionSpain · France · Germany - Ongoing, recruitingTherapeutic use (Phase IV)
CALCIGRAN FORTE AND DOSING OF IMMUNOSUPPRESSIVE DRUGS IN KIDNEY TRANSPLANT RECIPIENTS
This study is looking at how a common calcium supplement, Calcigran Forte, affects the levels of medicines taken by people who have had a kidney transplant. We want to make sure these important drugs work as well as they should.
For: Kidney transplantationNorway - Ongoing, recruitingTherapeutic use (Phase IV)
(IPCOM) Influence of Proton pump inhibitor CO-medication on the absorption of innovator and generic formulations of Mycophenolate mofetil
This study looks at how a common stomach acid medicine might affect how well the body absorbs different versions of mycophenolate mofetil. This drug is used by people who have had organ transplants. We're comparing original and generic versions of the transplant medicine.
For: Post Transplantation PatientsNetherlands - Ongoing, recruitingTherapeutic use (Phase IV)
Immunosuppressive drug bioequivalence in kidney transplant recipients – Prograf and CellCept
This study looks at how well different versions of medicines (Prograf and CellCept) used after a kidney transplant are absorbed by the body. It helps make sure new versions work just as well as existing ones to protect your new kidney.
For: Organ transplantationNorway